European Immunization Week 2018- Statement of Guido Rasi, Executive Director, European Medicines Agency

Posted on: 26/04/2018 - 13:27

Vaccines matter for each of us: yearly, they prevent 2.7 million people from contracting measles, one million from getting whooping cough and two million babies from getting tetanus. They eradicated smallpox. They stopped polio, a dreadful disease affecting millions of children, in almost all... more

Field of Interest: European Union Medical News
Type: News Feed

Human medicines European public assessment report (EPAR): Seffalair Spiromax, salmeterol,fluticasone propionate, Date of authorisation: 26/03/2021, Revision: 4, Status: Authorised

Submitted by Anonymous (not verified) on 1 September 2026 - 14:44

Human medicines European public assessment report (EPAR): Seffalair Spiromax, salmeterol,fluticasone propionate, Date of authorisation: 26/03/2021, Revision: 4, Status: Authorised

ACT EU multi-stakeholder platform annual meeting, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, 22 October 2026

Submitted by Anonymous (not verified) on 1 September 2026 - 12:50

ACT EU multi-stakeholder platform annual meeting, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, 22 October 2026

Human medicines European public assessment report (EPAR): Aujemflu, Influenza vaccine (surface antigen, inactivated, adjuvanted, prepared in cell culture), Date of authorisation: 20/08/2026, Status: Authorised

Submitted by Anonymous (not verified) on 1 September 2026 - 12:40

Human medicines European public assessment report (EPAR): Aujemflu, Influenza vaccine (surface antigen, inactivated, adjuvanted, prepared in cell culture), Date of authorisation: 20/08/2026, Status: Authorised

Human medicines European public assessment report (EPAR): Zadenvi, denosumab, Date of authorisation: 26/06/2025, Revision: 2, Status: Authorised

Submitted by Anonymous (not verified) on 1 September 2026 - 11:30

Human medicines European public assessment report (EPAR): Zadenvi, denosumab, Date of authorisation: 26/06/2025, Revision: 2, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More
randomness